Marker Therapeutics, Inc.’s common stock is listed on the Nasdaq Capital Market under the ticker symbol “MRKR”.
The company changed its name from TapImmune Inc. to Marker Therapeutics, Inc. on October 17, 2018.
The Company is headquartered in Houston, TX.
Marker Therapeutics is incorporated under the laws of the state of Delaware.
You can view the Management, Board of Directors, and Scientific Advisory Board by visiting our website.
Marker’s fiscal year end is December 31.
The CUSIP number is 57055L 107.
American Stock Transfer & Trust Company, LLC (AST):
ONLINE ACCOUNT ACCESS:
Accessing the AST website is designed to be simple and secure. In order to access your account online, please follow these steps:
Step 1: Go to http://www.astfinancial.com
Step 2: Click Login located at the top right hand corner of the page.
Step 3: Click Individuals on the login page as your user type.
Step 4: Click Register under Shareholder Central and complete the short registration process to create your unique login ID. If you are a non – U.S. shareholder please select click here on the top left hand corner of the page and complete the short registration process. Your PIN number will then be mailed to the address of record for the account.
*Please note the following classifications of ownership do not have online access to account information: Individual IRAs, Corporate Entities, Non-Resident U.S. Citizens, Resident Aliens, and U.S. Citizens Living Abroad.
TELEPHONE AND E-MAIL ASSISTANCE:
You may reach an AST representative by dialing (800) 937-5449 or by dialing (718) 921-8124. You can also e-mail AST at help@astfinancial.com.
Customer service representatives are available 8 a.m. to 8 p.m. Eastern Time, Monday through Friday.
MAIL INQUIRIES:
To contact AST via postal mail:
Marker Therapeutics, Inc.
c/o AST
6201 15th Avenue
Brooklyn, NY 11219
Quarterly & Annual Reports and other investor materials are available under Financial Filings of the Investors section of our website. Additionally, all SEC filings can also be accessed directly from the SEC at www.sec.gov.